ITGAM and neoplasm: To examine the tumor-specific responses, the effects of Rv2299c on the proportions among splenocytes of CD4+ T cells (Figure 2C), CD8+ T cells (Figure 2D), CD4+CD25+ Tregs (Figure 3A), CD4+FoxP3+ Tregs (Figure 3B), and CD11b+Gr1+ myeloid-derived suppressor cells (MDSCs) (Figure 3C) were evaluated in injected mice.